



FOR IMMEDIATE RELEASE

August 1, 2024

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Sayoko Sasaki Vice President, Corporate Communications Phone +81-3-3817-5120

REVENUE OF LEQEMBI® (PRELIMINARY BASIS)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) in the first quarter of fiscal year 2024 (April 1, 2024 – June 30, 2024) was JPY 6.3 billion (pre-audit basis), which was approximately 2.2 times higher than the revenue in the previous quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024).

This information is being disclosed in conjunction with today's announcement of the second quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the first quarter of fiscal year 2024, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled on August 2, 2024.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
